Application No.: 10/584,028 Docket No.: 1254-0318PUS1
Reply to Office Action of November 15, 2010 Page 2 of 7

AMENDMENTS TO THE CLAIMS

1-11. (Cancelled)

12. (Currently Amended) A method for differentiating mammalian bone marrow cells or cord blood-derived cells into myocardial precursor cells and/or myocardial cells without genetic engineering comprising:

culturing said bone marrow cells or cord blood-derived cells with fat-cells, fat precursor cells, and somatic stem cells Lin-negative, c-Kit-negative, and β 1 integrin-positive cells isolated from mammalian fat tissues, wherein said bone marrow cells or cord blood-derived cells are induced to differentiate into myocardial precursor cells and/or myocardial cells, and

wherein the cord blood-derived cells are mononuclear cells, that can be induced to differentiate into myocardial precursor cells and/or myocardial cells, and wherein the mammalian bone marrow cells are mesenchymal stem cells or hematopoietic stem cells.

- 13. (Previously Presented) The method according to claim 12, wherein culture is conducted for at least 1 day using a culture solution containing serum or any substitute thereof.
- 14. (Previously Presented) The method according to claim 13, wherein culture is conducted with the addition of at least one cytokine to a culture solution.
- 15. (Previously Presented) The method according to claim 14, wherein the cytokine is selected from the group consisting of members of the EGF family, members of the TGF-β family, members of the IL family, members of the VEGF family, members of the PDGF family, members of the Ephrin family, and SCF.

16-17. (Cancelled)

18. (Previously Presented) The method according to claim 12, wherein the bone marrow cells or cord blood-derived cells are mixed with the cells isolated from fat tissues at a ratio of 1:1 to 1:10. Application No.: 10/584,028 Docket No.: 1254-0318PUS1
Reply to Office Action of November 15, 2010 Page 3 of 7

19. (Previously Presented) The method according to claim 12, wherein the myocardial

precursor cells and/or myocardial cells are sarcomeric actin-positive cells.

20. (Withdrawn) Myocardial precursor cells and/or myocardial cells prepared by the

method according to claim 12.

21. (Withdrawn) The myocardial precursor cells and/or myocardial cells according to

claim 20, which can be transplanted into mammalian adults.

22. (Withdrawn) A method for evaluating the effects of a test substance on myocardial

precursor cells and/or myocardial cells by adding the test substance to the myocardial precursor

cells and/or myocardial cells according to claim 20.

23. (Previously Presented) The method according to claim 15, wherein said cytokine is a

member of the EGF family selected from EGF, TGF-α, HB-EGF, FGF, or HGF.

24. (Withdrawn) The method according to claim 15, wherein said cytokine is a member

members of the PDGF family selected from PDGF-AB or PDGF-BB.

25. (Previously Presented) The method according to claim 12, wherein said mammalian

bone marrow cells or cord blood-derived cells are derived from the same species as said cells

isolated from mammalian fat tissues or a culture supernatant thereof.

26. (Previously Presented) The method according to claim 12, wherein the bone marrow

cells or cord blood-derived cells are mixed with the cells isolated from fat tissues at a ratio of

1:4.

27. (Cancelled)

MSW/LTP/ciw